“…As described in the Introduction, Lotufo-Neto et al (1999) reported a meta-analysis of antidepressant effects of MAO inhibitors and pointed out the possibility that non-selective MAO inhibitors are more effective than RIMA. Our results are consistent with their meta-analysis results.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, Larsen et al (1991) reported that RIMA has equal antidepressant effects to those of irreversible MAO inhibitors. However, Lotufo-Neto et al (1999) examined antidepressant effects of MAO inhibitors in a 4 meta-analysis and described the possibility that non-selective MAO inhibitors are more effective than RIMA. Consequently, it is likely that MAO-B inhibition also contributes to an antidepressant effect.…”
Section: Consequently Mao Inhibitors Have Been Used Only Infrequentlmentioning
“…As described in the Introduction, Lotufo-Neto et al (1999) reported a meta-analysis of antidepressant effects of MAO inhibitors and pointed out the possibility that non-selective MAO inhibitors are more effective than RIMA. Our results are consistent with their meta-analysis results.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, Larsen et al (1991) reported that RIMA has equal antidepressant effects to those of irreversible MAO inhibitors. However, Lotufo-Neto et al (1999) examined antidepressant effects of MAO inhibitors in a 4 meta-analysis and described the possibility that non-selective MAO inhibitors are more effective than RIMA. Consequently, it is likely that MAO-B inhibition also contributes to an antidepressant effect.…”
Section: Consequently Mao Inhibitors Have Been Used Only Infrequentlmentioning
“…Even though it was never introduced into the US, moclobemide has been used successfully in other parts of the world (Chen & Ruch, 1993). In most countries, still selective serotonin reuptake inhibitors (SSRIs) were first-line treatments, except for Finland and Australia where moclobemide is widely used as first antidepressant therapy (Lotufo-Neto, Trivedi & Thase, 1999). Moclobemide is in use in many countries and is typically prescribed in the range of 300 to 450 mg/day with optimal benefit in some patients at doses of greater or equal to 900 mg/day.…”
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.
“…Moclobemide has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and social phobia. Overall, moclobemide appears to be safe and devoid of major side effects, although it is considered as a mild antidepressant, better tolerated by older patients [175][176][177][178][179][180][181]. Moclobemide undergoes extensive metabolism with less than 1 % of the dose being excreted unchanged.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.